# DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV

> **NCT04433780** · PHASE3 · COMPLETED · sponsor: **Professor Francois Venter** · enrollment: 133 (actual)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate

## Key facts

- **NCT ID:** NCT04433780
- **Lead sponsor:** Professor Francois Venter
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-04
- **Primary completion:** 2023-02-20
- **Final completion:** 2023-03-31
- **Target enrollment:** 133 (ACTUAL)
- **Last updated:** 2023-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04433780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04433780, "DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04433780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*